Catalyst
Slingshot members are tracking this event:
Alexion (ALXN) Presents Top-Line Phase 2/3 PROTECT Data Evaluating Eculizumab (Soliris®) For The Prevention Of Delayed Graft Function (DGF) After Kidney Transplantation
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALXN |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 21, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Top-line Data, Phase 2/3, Protect, Eculizumab, Soliris, Delayed Graft Function, Dgf, Kidney Transplantation
